Evidence map›Paper›PMID 38787272›Full record

ArticlePathogens (Basel, Switzerland)2024

A Comparison of RML Prion Inactivation Efficiency by Heterogeneous and Homogeneous Photocatalysis.

Ioannis Paspaltsis, Eirini Kanata, Sotirios Sotiriadis, Susana Silva Correia, Matthias Schmitz, Inga Zerr, Dimitra Dafou, Konstantinos Xanthopoulos, Theodoros Sklaviadis

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ioannis PaspaltsisLaboratory of Pharmacology, Department of Pharmacy, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Eirini KanataLaboratory of Pharmacology, Department of Pharmacy, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0001-7363-9380
Sotirios SotiriadisLaboratory of Pharmacology, Department of Pharmacy, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Susana Silva CorreiaDepartment of Neurology, University Medicine Goettingen, German Center for Neurodegenerative Diseases (DZNE), 37075 Göttingen, Germany.
Matthias SchmitzDepartment of Neurology, University Medicine Goettingen, German Center for Neurodegenerative Diseases (DZNE), 37075 Göttingen, Germany.ORCID 0000-0002-5502-681X
Inga ZerrDepartment of Neurology, University Medicine Goettingen, German Center for Neurodegenerative Diseases (DZNE), 37075 Göttingen, Germany.ORCID 0000-0002-6722-2463
Dimitra DafouDepartment of Genetics, Development and Molecular Biology, School of Biology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0003-4170-0612
Konstantinos XanthopoulosLaboratory of Pharmacology, Department of Pharmacy, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0001-8759-8962
Theodoros SklaviadisLaboratory of Pharmacology, Department of Pharmacy, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

Funding

European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, call RESEARCH-CREATE-INNOVATE T1EDK-02678
6 · The paper itself

Abstract

Prions are proteinaceous pathogens responsible for a variety of devastating diseases in mammals, including scrapie in sheep and goats, chronic wasting disease in cervids, and Creutzfeldt-Jakob disease (CJD) in humans. They are characterized by their exceptional persistence to common inactivation procedures. This applies to all possible sources of prion contamination as prions may be present in the tissues and biological fluids of infected individuals. Hence, efficient prion inactivation procedures are still being sought to minimize the risk of intra- or inter-species transmission. In the past, photocatalytic treatment has been proven to be capable of efficiently oxidizing and inactivating prions. In the present study, the efficacy of homogeneous photo-Fenton-based photocatalysis as well as heterogeneous photocatalysis with TiO

Indexed as

ScrapieAnimalsBiological AssayCatalysisHydrogen PeroxideIronMicePrionsTitaniumFenton's reagentHydrogen PeroxideIronPrionsTitaniumtitanium dioxideheterogeneous photocatalysishomogeneous photocatalysisphoto-Fenton reagentprion decontaminationprion inactivationRML prionTiO2 photocatalysis

Identifiers

PMID38787272
PMCPMC11124347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.